Even in stable times, Pharma supply chains are fragile and as complex as they can get. As the Covid-19 pandemic continues to wreak havoc on countries around the world, Pharmaceutical supply chains have come under immense pressure. In this article, we would cover some of the key challenges which Pharma supply chain Executives face on the frontlines, and how Analytics and Data Science can be leveraged to overcome these challenges.

Covid-19 disruptions are going to test the strength of Pharma Supply Chains:

  • Stockouts are a real risk: According to a study by University of Minnesota, 80% of the drugs marketed in the United States, including 19 of the 20 top-selling brand names, are made overseas. The global nature of supply chains, regulatory challenges and high uncertainty makes stockouts a real risk – jeopardizing the health of millions of patients who depend on life saving drugs
  • Operational metrics for Pharma Cos would need drastic improvement: With an average inventory of 258 DoH , the Pharma industry has one of the largest inventory stockpiles – 2-4X larger than FMCG at 72 DoH. However, given the staggering scale of this pandemic and the real risk of stockouts, Pharmas would need to rethink and optimize their inventory allocation strategies to ensure that the current inventory of drugs is allocated to the channels and regions with the most urgent need
  • Shift in Consumption Patterns: As drugs are identified as potential treatments for Covid-19, the demand may quickly surpass the supply.  These drastic shifts in consumption patterns have already been observed with Covid-19 treatment candidates e.g Genentech’s  Actemra, Sanofi & Regeneron‘s Kevzara and Gilead’s Remdesivir, an experimental drug for Covid-19. In early April, the FDA reported shortages of hydroxychloroquine and chloroquine, antimalarial drugs that were speculated to be front-runners for a possible Covid-19 therapeutic. This shortage has impacted patients with Lupus, where chloroquine is a life saving drug
  • Long-term Cyclicity of a Recurring Pandemic: Taking a page from history, the Spanish Flu epidemic hit in waves, the second wave more lethal than the first.  If the Covid-19 virus proves to be seasonal, the impact of the pandemic might happen in waves over a 1-3 year period before stabilizing. Pharma Cos should be prepared for detecting and responding to new drivers of demand with very high momentum. Some new drivers of demand could be – preference for self administered drugs due to a drop in hospital visits, higher propensity for hoarding and increased demand for normal uses of certain drugs e.g  acetaminophen to treat fever & flu symptoms

Given the scale of disruption, how can Pharma Supply Chain Executives approach these challenges ?

A combination of strategic and operational moves leveraging Analytics and Data Science capabilities will help you get to the critical insights necessary for getting started.

  • Gain a realistic view of your current state: Creating a transparent view of your supply chain and assessing the current state is your first step. Quick dashboards and ad-hoc analysis will give you a perspective of what is happening on the ground, and in the moment. The views should be built to assess 3 key stages in your Supply chain:
    • Multi-tier Supply Assessment– What are the most critical components of Supply? What is the risk of interruption? What is the next best action for high risk Suppliers?
    • Inventory Audit– Where does your allocated Inventory lie both in-house and with distributors? What amount of this Inventory is finished goods vs blocked  for quality control and testing? What is the volume of Inventory in transit?
    • Demand – What is the most realistic estimate of customer demand?  Are there any specific NDCs with disproportionate impact on demand? How is the demand distributed at the Distributor, Geo and NDC level? Are the underlying assumptions of demand signals still robust? What are the emerging drivers of demand which might be getting missed?
  • Break down your perspective – Short term and Medium term: Organize your efforts with a Covid-19 Command center which would provide a perspective on  ‘Short term Crisis management’ and ‘Medium term Planning Ahead’ initiatives. This would ensure that teams on the ground continue to have bias for action, without  getting blindsided by what’s coming ahead.
    • Crisis Management teams– Focus on the most immediate tasks where speed is of essence. This team would focus on the most high impact disruptions and build quick dashboards/reports to get a transparent view of the current situation and generate critical insights for operational teams on the field
    • Planning Ahead teams– Look ahead to answer questions on mid-term and long term impact – like testing underlying assumptions, bringing in new intelligence from external analysis, identifying and integrating new signals and data sources into the analysis and developing scenarios for the future
  • Develop Scenarios for multiple versions of the future: The nature of the current Covid-19 pandemic is such that the arc of impact would be varied and staggered across the world. Take the US for example, every state and county is experiencing the pandemic differently. Hence, supply chain teams need to develop a scenario based decision making frame to assess how the pandemic would pan out, and what are their best moves at the moment . Here , the scenarios need to be built at 2 levels :
    • External Scenarios– Evaluate impact of the pandemic and effectiveness of the response at macro and micro levels across countries, states and down to county levels on key metrics like demand and supply
    • Internal Scenarios – Simulate impact of moves based on a Pharma’s ability to respond to the crisis. This would involve tweaking Supply chain parameters like manufacturing and shipping lead times, safety stock assumptions to identify what is the next best action that should be taken by Channel Inventory, Demand Planning and Manufacturing teams in the medium and long term
  • Factor for Uncertainty and Anomalies:  During times of uncertainty , one of the most powerful tools in the arsenal of Data Science is Anomaly detection. Over here, the unknowns are shifts in consumption patterns and cyclicity of recurring pandemic which would be hard to detect with human judgement. Once fed with the historic data, powerful ML algorithms can help you quickly spot unknown unknowns in your data, down to the most granular levels of detail – helping you set up algorithmic trigger points to flag alerts. This should be one of the key pillars of response for the  ‘Medium term Planning Ahead’ workstream. Some examples of metrics to be looked at:
    • Analyzing past demand patterns with anomaly detection models would help quickly spot which NDCs are impacted by the shifts in consumption patterns to predict stock outs at zip code level
    • Anomaly detection algorithms to flag emerging new hotspots of emerging Covid-19 cases at a country, state and county level impacting distribution and logistics
  • Be prepared for a fundamental change in the nature of your Data: With more than 3 billion people in lockdown, this epidemic will bring dramatic changes in patient, distributor and regulatory behaviors around the world.  Covid-19 is a perfect example of a ‘structural break’ in your time series data – with implications both in the short and the long term. Pharma companies might need to look for unconventional sources of data for getting insights during times of uncertainty. For example  – Google Search trends have been found to be good predictors of demand for certain types of drugs, and can also help us find emerging Covid-19 outbreaks. They can also reveal symptoms like ‘loss of smell’ that at first went undetected.

The current crisis has plunged entire countries and the Pharma industry into times of uncertainty. Building a transparent view of the current state, scenario based planning and proactive detection of anomalies are key tools on the frontlines for defense.

By acting intentionally today and using the tools at our disposal, Pharma companies can weather this crisis, emerging stronger and building resilience for the future. And in the process, enhancing and saving many lives around the world.

Afrozy Ara
Afrozy Ara
Sr. Director, Analytics & Big Data
Recruitment Fraud Alert